Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy
Tumor biomarkers represent effective tools for diagnostics and follow-up monitoring of patients with non-small cell lung cancer (NSCLC). We focused on evaluating the predictive and prognostic role of the seven following tumor biomarkers: carcinoembryonic antigen (CEA), cytokeratin-19 fragment (CYFRA...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2016-01, Vol.36 (1), p.461-466 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 466 |
|---|---|
| container_issue | 1 |
| container_start_page | 461 |
| container_title | Anticancer research |
| container_volume | 36 |
| creator | Fiala, Ondrej Pesek, Milos Finek, Jindrich Svaton, Martin Sorejs, Ondrej Bortlicek, Zbynek Kucera, Radek Topolcan, Ondrej |
| description | Tumor biomarkers represent effective tools for diagnostics and follow-up monitoring of patients with non-small cell lung cancer (NSCLC). We focused on evaluating the predictive and prognostic role of the seven following tumor biomarkers: carcinoembryonic antigen (CEA), cytokeratin-19 fragment (CYFRA 21-1), fragments of cytokeratin 8, 18 and 19 (MonoTotal), neuron-specific enolase (NSE), chromogranin A, thymidine kinase (TK) and squamous cell carcinoma antigen (SCCA) in patients with advanced-stage NSCLC treated with pemetrexed-based chemotherapy.
In total, 114 patients with advanced-stage (IIIB or IV) non-squamous NSCLC treated with pemetrexed-based chemotherapy (monotherapy or combination with a platinum derivative) were included. Comparison of progression-free (PFS) and overall survival (OS) according to the level of assessed tumor markers was performed using the log-rank test.
We recorded significantly shorter OS for patients with high pretreatment levels of CYFRA 21-1 (10.3 vs. 23.4 months; p |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1753012435</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1753012435</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-3ac71310c2895048c0f9879701347702d727907c57925652a73fb403ce7561c3</originalsourceid><addsrcrecordid>eNo10E1LwzAcBvAgiJvTryA5einkpWma4yi-wdTBei9Z-u8WXZqapOpOfnU3pqcHHn48h-cMTalUNJOCkwm6jPGNkKJQJb9AE1ZIxkjJpuhnGfym9zFZg1d209vOGt0bwL7DKwijw_XofMDPOrxDiNj2eKmThT5F_GXTFs_bz6Nvs5j0BvDLqlpUuA6gE7QnsQQHKcD3wax1PLTVFpxPWwh62F-h807vIlz_5QzV93d19ZgtXh-eqvkiGxilKePaSMopMaxUguSlIZ0qpZKE8lxKwlrJpCLSCKmYKATTknfrnHADUhTU8Bm6Pc0OwX-MEFPjbDSw2-ke_BgbenyJspyLA735o-PaQdsMwTod9s3_Z_wXgstmpA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1753012435</pqid></control><display><type>article</type><title>Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Fiala, Ondrej ; Pesek, Milos ; Finek, Jindrich ; Svaton, Martin ; Sorejs, Ondrej ; Bortlicek, Zbynek ; Kucera, Radek ; Topolcan, Ondrej</creator><creatorcontrib>Fiala, Ondrej ; Pesek, Milos ; Finek, Jindrich ; Svaton, Martin ; Sorejs, Ondrej ; Bortlicek, Zbynek ; Kucera, Radek ; Topolcan, Ondrej</creatorcontrib><description>Tumor biomarkers represent effective tools for diagnostics and follow-up monitoring of patients with non-small cell lung cancer (NSCLC). We focused on evaluating the predictive and prognostic role of the seven following tumor biomarkers: carcinoembryonic antigen (CEA), cytokeratin-19 fragment (CYFRA 21-1), fragments of cytokeratin 8, 18 and 19 (MonoTotal), neuron-specific enolase (NSE), chromogranin A, thymidine kinase (TK) and squamous cell carcinoma antigen (SCCA) in patients with advanced-stage NSCLC treated with pemetrexed-based chemotherapy.
In total, 114 patients with advanced-stage (IIIB or IV) non-squamous NSCLC treated with pemetrexed-based chemotherapy (monotherapy or combination with a platinum derivative) were included. Comparison of progression-free (PFS) and overall survival (OS) according to the level of assessed tumor markers was performed using the log-rank test.
We recorded significantly shorter OS for patients with high pretreatment levels of CYFRA 21-1 (10.3 vs. 23.4 months; p<0.001), NSE (1.6 vs. 13.5 months; p=0.003) and TK (11.3 vs. 23.4 months; p=0.003).
CYFRA 21-1, NSE and TK are feasible biomarkers for estimation of a patient's overall prognosis, however, none of the measured serum tumor markers were able to predict the efficacy of pemetrexed-based chemotherapy.</description><identifier>EISSN: 1791-7530</identifier><identifier>PMID: 26722082</identifier><language>eng</language><publisher>Greece</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor - blood ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - pathology ; Disease Progression ; Female ; Humans ; Lung Neoplasms - drug therapy ; Lung Neoplasms - pathology ; Male ; Middle Aged ; Pemetrexed ; Prognosis</subject><ispartof>Anticancer research, 2016-01, Vol.36 (1), p.461-466</ispartof><rights>Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26722082$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fiala, Ondrej</creatorcontrib><creatorcontrib>Pesek, Milos</creatorcontrib><creatorcontrib>Finek, Jindrich</creatorcontrib><creatorcontrib>Svaton, Martin</creatorcontrib><creatorcontrib>Sorejs, Ondrej</creatorcontrib><creatorcontrib>Bortlicek, Zbynek</creatorcontrib><creatorcontrib>Kucera, Radek</creatorcontrib><creatorcontrib>Topolcan, Ondrej</creatorcontrib><title>Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>Tumor biomarkers represent effective tools for diagnostics and follow-up monitoring of patients with non-small cell lung cancer (NSCLC). We focused on evaluating the predictive and prognostic role of the seven following tumor biomarkers: carcinoembryonic antigen (CEA), cytokeratin-19 fragment (CYFRA 21-1), fragments of cytokeratin 8, 18 and 19 (MonoTotal), neuron-specific enolase (NSE), chromogranin A, thymidine kinase (TK) and squamous cell carcinoma antigen (SCCA) in patients with advanced-stage NSCLC treated with pemetrexed-based chemotherapy.
In total, 114 patients with advanced-stage (IIIB or IV) non-squamous NSCLC treated with pemetrexed-based chemotherapy (monotherapy or combination with a platinum derivative) were included. Comparison of progression-free (PFS) and overall survival (OS) according to the level of assessed tumor markers was performed using the log-rank test.
We recorded significantly shorter OS for patients with high pretreatment levels of CYFRA 21-1 (10.3 vs. 23.4 months; p<0.001), NSE (1.6 vs. 13.5 months; p=0.003) and TK (11.3 vs. 23.4 months; p=0.003).
CYFRA 21-1, NSE and TK are feasible biomarkers for estimation of a patient's overall prognosis, however, none of the measured serum tumor markers were able to predict the efficacy of pemetrexed-based chemotherapy.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomarkers, Tumor - blood</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pemetrexed</subject><subject>Prognosis</subject><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo10E1LwzAcBvAgiJvTryA5einkpWma4yi-wdTBei9Z-u8WXZqapOpOfnU3pqcHHn48h-cMTalUNJOCkwm6jPGNkKJQJb9AE1ZIxkjJpuhnGfym9zFZg1d209vOGt0bwL7DKwijw_XofMDPOrxDiNj2eKmThT5F_GXTFs_bz6Nvs5j0BvDLqlpUuA6gE7QnsQQHKcD3wax1PLTVFpxPWwh62F-h807vIlz_5QzV93d19ZgtXh-eqvkiGxilKePaSMopMaxUguSlIZ0qpZKE8lxKwlrJpCLSCKmYKATTknfrnHADUhTU8Bm6Pc0OwX-MEFPjbDSw2-ke_BgbenyJspyLA735o-PaQdsMwTod9s3_Z_wXgstmpA</recordid><startdate>201601</startdate><enddate>201601</enddate><creator>Fiala, Ondrej</creator><creator>Pesek, Milos</creator><creator>Finek, Jindrich</creator><creator>Svaton, Martin</creator><creator>Sorejs, Ondrej</creator><creator>Bortlicek, Zbynek</creator><creator>Kucera, Radek</creator><creator>Topolcan, Ondrej</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201601</creationdate><title>Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy</title><author>Fiala, Ondrej ; Pesek, Milos ; Finek, Jindrich ; Svaton, Martin ; Sorejs, Ondrej ; Bortlicek, Zbynek ; Kucera, Radek ; Topolcan, Ondrej</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-3ac71310c2895048c0f9879701347702d727907c57925652a73fb403ce7561c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomarkers, Tumor - blood</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pemetrexed</topic><topic>Prognosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fiala, Ondrej</creatorcontrib><creatorcontrib>Pesek, Milos</creatorcontrib><creatorcontrib>Finek, Jindrich</creatorcontrib><creatorcontrib>Svaton, Martin</creatorcontrib><creatorcontrib>Sorejs, Ondrej</creatorcontrib><creatorcontrib>Bortlicek, Zbynek</creatorcontrib><creatorcontrib>Kucera, Radek</creatorcontrib><creatorcontrib>Topolcan, Ondrej</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fiala, Ondrej</au><au>Pesek, Milos</au><au>Finek, Jindrich</au><au>Svaton, Martin</au><au>Sorejs, Ondrej</au><au>Bortlicek, Zbynek</au><au>Kucera, Radek</au><au>Topolcan, Ondrej</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2016-01</date><risdate>2016</risdate><volume>36</volume><issue>1</issue><spage>461</spage><epage>466</epage><pages>461-466</pages><eissn>1791-7530</eissn><abstract>Tumor biomarkers represent effective tools for diagnostics and follow-up monitoring of patients with non-small cell lung cancer (NSCLC). We focused on evaluating the predictive and prognostic role of the seven following tumor biomarkers: carcinoembryonic antigen (CEA), cytokeratin-19 fragment (CYFRA 21-1), fragments of cytokeratin 8, 18 and 19 (MonoTotal), neuron-specific enolase (NSE), chromogranin A, thymidine kinase (TK) and squamous cell carcinoma antigen (SCCA) in patients with advanced-stage NSCLC treated with pemetrexed-based chemotherapy.
In total, 114 patients with advanced-stage (IIIB or IV) non-squamous NSCLC treated with pemetrexed-based chemotherapy (monotherapy or combination with a platinum derivative) were included. Comparison of progression-free (PFS) and overall survival (OS) according to the level of assessed tumor markers was performed using the log-rank test.
We recorded significantly shorter OS for patients with high pretreatment levels of CYFRA 21-1 (10.3 vs. 23.4 months; p<0.001), NSE (1.6 vs. 13.5 months; p=0.003) and TK (11.3 vs. 23.4 months; p=0.003).
CYFRA 21-1, NSE and TK are feasible biomarkers for estimation of a patient's overall prognosis, however, none of the measured serum tumor markers were able to predict the efficacy of pemetrexed-based chemotherapy.</abstract><cop>Greece</cop><pmid>26722082</pmid><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1791-7530 |
| ispartof | Anticancer research, 2016-01, Vol.36 (1), p.461-466 |
| issn | 1791-7530 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1753012435 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Aged Aged, 80 and over Biomarkers, Tumor - blood Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Disease Progression Female Humans Lung Neoplasms - drug therapy Lung Neoplasms - pathology Male Middle Aged Pemetrexed Prognosis |
| title | Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T00%3A27%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20Significance%20of%20Serum%20Tumor%20Markers%20in%20Patients%20with%20Advanced-stage%20NSCLC%20Treated%20with%20Pemetrexed-based%20Chemotherapy&rft.jtitle=Anticancer%20research&rft.au=Fiala,%20Ondrej&rft.date=2016-01&rft.volume=36&rft.issue=1&rft.spage=461&rft.epage=466&rft.pages=461-466&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1753012435%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1753012435&rft_id=info:pmid/26722082&rfr_iscdi=true |